Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma

Ji Soo Choi, Eun Kyung Kim, Hee Jung Moon, Jin Young Kwak

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Recently, higher body mass index (BMI) has been associated with aggressive pathologic features of papillary thyroid carcinoma. The aim of this study was to clarify the relationship between BMI and aggressive pathologic features of papillary thyroid microcarcinoma (PTMC) and to evaluate whether the BMI can be a prognostic factor of PTMC. This retrospective study included 612 PTMC patients who underwent surgical excision at a referral center between April 2006 and December 2007. Patients were grouped according to BMI (<25 or ≥25 kg/m2). Multivariable logistic regression analysis was performed to determine independent predictors of aggressive pathologic features (advanced stage, extrathyroidal extension, and lymph node metastasis), with adjustment for age, gender, tumor size, multifocality, thyroid stimulating hormone (TSH) level, and BMI (value/group). PTMC patients with a BMI ≥ 25 kg/m2 showed significantly higher prevalences of extrathyroidal extension, advanced pathologic TNM stage, and male gender, compared to those of patients with a BMI < 25 kg/m2. Lymph node metastasis and mean TSH level were not significantly different between the two BMI subgroups. In multivariable analysis, the BMI ≥ 25 kg/m2 group was positively associated with the presence of extrathyroidal extension (adjusted odds ratio 1.49, P = 0.05). Higher BMI was associated with extrathyroidal extension in PTMC patients. This study suggests that the BMI could be considered as a prognostic factor for predicting the presence of extrathyroidal extension and it may help decide the appropriate surgical extent for PTMC patients.

Original languageEnglish
Pages (from-to)264-271
Number of pages8
JournalEndocrine
Volume48
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Body Mass Index
Thyrotropin
Lymph Nodes
Neoplasm Metastasis
Papillary Thyroid Microcarcinoma
Referral and Consultation
Retrospective Studies
Logistic Models
Odds Ratio
Regression Analysis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{c7214e5cd88b41e284982080a40a2447,
title = "Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma",
abstract = "Recently, higher body mass index (BMI) has been associated with aggressive pathologic features of papillary thyroid carcinoma. The aim of this study was to clarify the relationship between BMI and aggressive pathologic features of papillary thyroid microcarcinoma (PTMC) and to evaluate whether the BMI can be a prognostic factor of PTMC. This retrospective study included 612 PTMC patients who underwent surgical excision at a referral center between April 2006 and December 2007. Patients were grouped according to BMI (<25 or ≥25 kg/m2). Multivariable logistic regression analysis was performed to determine independent predictors of aggressive pathologic features (advanced stage, extrathyroidal extension, and lymph node metastasis), with adjustment for age, gender, tumor size, multifocality, thyroid stimulating hormone (TSH) level, and BMI (value/group). PTMC patients with a BMI ≥ 25 kg/m2 showed significantly higher prevalences of extrathyroidal extension, advanced pathologic TNM stage, and male gender, compared to those of patients with a BMI < 25 kg/m2. Lymph node metastasis and mean TSH level were not significantly different between the two BMI subgroups. In multivariable analysis, the BMI ≥ 25 kg/m2 group was positively associated with the presence of extrathyroidal extension (adjusted odds ratio 1.49, P = 0.05). Higher BMI was associated with extrathyroidal extension in PTMC patients. This study suggests that the BMI could be considered as a prognostic factor for predicting the presence of extrathyroidal extension and it may help decide the appropriate surgical extent for PTMC patients.",
author = "Choi, {Ji Soo} and Kim, {Eun Kyung} and Moon, {Hee Jung} and Kwak, {Jin Young}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12020-014-0293-z",
language = "English",
volume = "48",
pages = "264--271",
journal = "Endocrine",
issn = "0969-711X",
publisher = "Humana Press",
number = "1",

}

Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. / Choi, Ji Soo; Kim, Eun Kyung; Moon, Hee Jung; Kwak, Jin Young.

In: Endocrine, Vol. 48, No. 1, 01.01.2014, p. 264-271.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma

AU - Choi, Ji Soo

AU - Kim, Eun Kyung

AU - Moon, Hee Jung

AU - Kwak, Jin Young

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Recently, higher body mass index (BMI) has been associated with aggressive pathologic features of papillary thyroid carcinoma. The aim of this study was to clarify the relationship between BMI and aggressive pathologic features of papillary thyroid microcarcinoma (PTMC) and to evaluate whether the BMI can be a prognostic factor of PTMC. This retrospective study included 612 PTMC patients who underwent surgical excision at a referral center between April 2006 and December 2007. Patients were grouped according to BMI (<25 or ≥25 kg/m2). Multivariable logistic regression analysis was performed to determine independent predictors of aggressive pathologic features (advanced stage, extrathyroidal extension, and lymph node metastasis), with adjustment for age, gender, tumor size, multifocality, thyroid stimulating hormone (TSH) level, and BMI (value/group). PTMC patients with a BMI ≥ 25 kg/m2 showed significantly higher prevalences of extrathyroidal extension, advanced pathologic TNM stage, and male gender, compared to those of patients with a BMI < 25 kg/m2. Lymph node metastasis and mean TSH level were not significantly different between the two BMI subgroups. In multivariable analysis, the BMI ≥ 25 kg/m2 group was positively associated with the presence of extrathyroidal extension (adjusted odds ratio 1.49, P = 0.05). Higher BMI was associated with extrathyroidal extension in PTMC patients. This study suggests that the BMI could be considered as a prognostic factor for predicting the presence of extrathyroidal extension and it may help decide the appropriate surgical extent for PTMC patients.

AB - Recently, higher body mass index (BMI) has been associated with aggressive pathologic features of papillary thyroid carcinoma. The aim of this study was to clarify the relationship between BMI and aggressive pathologic features of papillary thyroid microcarcinoma (PTMC) and to evaluate whether the BMI can be a prognostic factor of PTMC. This retrospective study included 612 PTMC patients who underwent surgical excision at a referral center between April 2006 and December 2007. Patients were grouped according to BMI (<25 or ≥25 kg/m2). Multivariable logistic regression analysis was performed to determine independent predictors of aggressive pathologic features (advanced stage, extrathyroidal extension, and lymph node metastasis), with adjustment for age, gender, tumor size, multifocality, thyroid stimulating hormone (TSH) level, and BMI (value/group). PTMC patients with a BMI ≥ 25 kg/m2 showed significantly higher prevalences of extrathyroidal extension, advanced pathologic TNM stage, and male gender, compared to those of patients with a BMI < 25 kg/m2. Lymph node metastasis and mean TSH level were not significantly different between the two BMI subgroups. In multivariable analysis, the BMI ≥ 25 kg/m2 group was positively associated with the presence of extrathyroidal extension (adjusted odds ratio 1.49, P = 0.05). Higher BMI was associated with extrathyroidal extension in PTMC patients. This study suggests that the BMI could be considered as a prognostic factor for predicting the presence of extrathyroidal extension and it may help decide the appropriate surgical extent for PTMC patients.

UR - http://www.scopus.com/inward/record.url?scp=84939885299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939885299&partnerID=8YFLogxK

U2 - 10.1007/s12020-014-0293-z

DO - 10.1007/s12020-014-0293-z

M3 - Article

C2 - 24858734

AN - SCOPUS:84939885299

VL - 48

SP - 264

EP - 271

JO - Endocrine

JF - Endocrine

SN - 0969-711X

IS - 1

ER -